GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (NAS:NEPH) » Definitions » Cyclically Adjusted PS Ratio

Nephros (Nephros) Cyclically Adjusted PS Ratio : 2.17 (As of Apr. 28, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Nephros Cyclically Adjusted PS Ratio?

As of today (2024-04-28), Nephros's current share price is $2.19. Nephros's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.01. Nephros's Cyclically Adjusted PS Ratio for today is 2.17.

The historical rank and industry rank for Nephros's Cyclically Adjusted PS Ratio or its related term are showing as below:

NEPH' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.22   Med: 1.26   Max: 9.22
Current: 2.17

During the past years, Nephros's highest Cyclically Adjusted PS Ratio was 9.22. The lowest was 0.22. And the median was 1.26.

NEPH's Cyclically Adjusted PS Ratio is ranked worse than
50.97% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 2.11 vs NEPH: 2.17

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nephros's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.310. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.01 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Nephros Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Nephros's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nephros Cyclically Adjusted PS Ratio Chart

Nephros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.89 7.29 5.87 1.18 3.43

Nephros Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 1.09 1.58 1.48 3.43

Competitive Comparison of Nephros's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, Nephros's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nephros's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nephros's Cyclically Adjusted PS Ratio falls into.



Nephros Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Nephros's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.19/1.01
=2.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nephros's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Nephros's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.31/129.4194*129.4194
=0.310

Current CPI (Dec. 2023) = 129.4194.

Nephros Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.226 99.695 0.293
201406 0.158 100.560 0.203
201409 0.132 100.428 0.170
201412 0.118 99.070 0.154
201503 0.132 99.621 0.171
201506 0.164 100.684 0.211
201509 0.088 100.392 0.113
201512 0.102 99.792 0.132
201603 0.110 100.470 0.142
201606 0.094 101.688 0.120
201609 0.088 101.861 0.112
201612 0.137 101.863 0.174
201703 0.133 102.862 0.167
201706 0.144 103.349 0.180
201709 0.152 104.136 0.189
201712 0.215 104.011 0.268
201803 0.160 105.290 0.197
201806 0.194 106.317 0.236
201809 0.242 106.507 0.294
201812 0.226 105.998 0.276
201903 0.248 107.251 0.299
201906 0.313 108.070 0.375
201909 0.402 108.329 0.480
201912 0.398 108.420 0.475
202003 0.294 108.902 0.349
202006 0.175 108.767 0.208
202009 0.235 109.815 0.277
202012 0.241 109.897 0.284
202103 0.277 111.754 0.321
202106 0.228 114.631 0.257
202109 0.257 115.734 0.287
202112 0.266 117.630 0.293
202203 0.211 121.301 0.225
202206 0.277 125.017 0.287
202209 0.234 125.227 0.242
202212 0.247 125.222 0.255
202303 0.359 127.348 0.365
202306 0.344 128.729 0.346
202309 0.358 129.860 0.357
202312 0.310 129.419 0.310

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nephros  (NAS:NEPH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Nephros Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Nephros's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nephros (Nephros) Business Description

Traded in Other Exchanges
Address
380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets. In medical markets, it sell water filtration products and waterborne pathogen detection products. In commercial markets, the company manufacture and sell water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The operating segments of the group are Water Filtration, Pathogen Detection and Renal Products of which key revenue is derived from Water Filtration segment.
Executives
Banks Robert R. Jr. director, officer: President and CEO C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Judy Krandel officer: Chief Financial Officer 320 W. 37TH STREET, 13TH FLOOR, NEW YORK NY 10018
Joseph Michael Harris director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Wesley S. Lobo officer: Chief Marketing Officer C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Tom Gwydir director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Andrew Astor officer: Chief Financial Officer 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Charles E Davidson director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp director, 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Gp Llc director, 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Oliver J. Spandow director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daniel S. D'agostino officer: Chief Financial Officer C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daron Evans director, officer: President and CEO C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Alisa Lask director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830

Nephros (Nephros) Headlines

From GuruFocus

Nephros First Quarter 2022 Financial Results Conference Call

By GuruFocusNews GuruFocusNews 04-27-2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

By GuruFocusNews GuruFocusNews 05-27-2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

By GuruFocusNews GuruFocusNews 05-17-2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

By GuruFocusNews GuruFocusNews 06-26-2022

Nephros Announces CEO Retirement and Succession Plan

By sperokesalga sperokesalga 05-08-2023